Video

Dr. Ramasamy discusses investigational oral testosterone treatment

Author(s):

Urology Times staff

Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.

In this video, Ranjith Ramasamy, MD, discusses SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule for which the FDA recently accepted a new drug application. Ramasamy is an associate professor of urology and director of male reproductive medicine and surgery at the University of Miami Miller School of Medicine.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Rido - stock.adobe.com
Around the Practice
Related Content
Use of testosterone does not lead to abnormal hematocrit levels
November 27th 2023

Use of testosterone does not lead to abnormal hematocrit levels

Hannah Clarke
"The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment," says Joshua Safer, MD, FACP, FACE.
Dr. Robert J. Hamilton on statin use in men starting ADT for prostate cancer
April 21st 2021

Dr. Robert J. Hamilton on statin use in men starting ADT for prostate cancer

Urology Times staff
Hamilton discusses findings from a recent study published in European Urology.
Study highlights how DTC online platforms often fail to convey risks of testosterone therapy
December 8th 2022

Study highlights how DTC online platforms often fail to convey risks of testosterone therapy

Northwestern Medicine
“While there’s benefit in improving access, there’s also potential for harm when providers fail to follow evidence-based guidelines, or when the benefits and risks of treatment are not appropriately communicated," said Joshua A. Halpern, MD.
FDA approves oral testosterone replacement therapy for hypogonadism
August 4th 2022

FDA approves oral testosterone replacement therapy for hypogonadism

Urology Times staff
Kyzatrex is an oral testosterone replacement therapy for the treatment of adult males with conditions associated with hypogonadism.
Novel testosterone undecanoate capsule launched in US hypogonadism market
June 9th 2022

Novel testosterone undecanoate capsule launched in US hypogonadism market

Jason M. Broderick
Testosterone undecanoate (Tlando), an oral testosterone replacement therapy, was approved in March 2022 for the treatment of men with hypogonadism.
FDA approves novel testosterone undecanoate capsule for hypogonadism
March 29th 2022

FDA approves novel testosterone undecanoate capsule for hypogonadism

Jason M. Broderick
The pivotal trial supporting approval of the oral testosterone undecanoate was Study 16-002, which included 95 hypogonadal males.
© 2025 MJH Life Sciences

All rights reserved.